SecBot SecBot
SECBOTREPLAY Home › Report › ESPR

ESPR · Esperion Therapeutics reported strong financial results for Q4 and…

Esperion Therapeutics, Inc. · PRESS-RELEASE filed Mar 10, 2026 at 06:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 10, 2026 at 06:00 ET

Esperion Therapeutics reported strong financial results for Q4 and full-year 2025, with total revenue growing 144% YoY in Q4 to $168.4 million and 21% for the full year to $403.1 million. U.S. net product revenue grew 38% YoY in both periods, driven by bempedoic acid franchise momentum. The company also announced an acquisition of Corstasis Therapeutics to expand its cardiovascular portfolio with Enbumyst™, a nasal spray diuretic for heart failure patients.

  • Q4 2025 total revenue grew 144% YoY to $168.4 million; full-year 2025 revenue grew 21% to $403.1 million
  • Q4 U.S. net product revenue grew ~38% YoY to $43.7 million; full-year U.S. net product revenue grew 38% to $159.6 million
  • Q4 retail prescription equivalents grew 34% YoY and 11.3% Q/Q
  • Net income of $61.8 million in Q4 2025 vs. net loss of $21.3 million in Q4 2024

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access